» Articles » PMID: 38302183

Nintedanib and Symptoms of Fibrotic Lung Disease: a Glimmer of Hope for Patients Living with Pulmonary Fibrosis

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2024 Feb 1
PMID 38302183
Authors
Affiliations
Soon will be listed here.
References
1.
King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

2.
Raghu G, Remy-Jardin M, Richeldi L, Thomson C, Inoue Y, Johkoh T . Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022; 205(9):e18-e47. PMC: 9851481. DOI: 10.1164/rccm.202202-0399ST. View

3.
Noble P, Albera C, Bradford W, Costabel U, Glassberg M, Kardatzke D . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779):1760-9. DOI: 10.1016/S0140-6736(11)60405-4. View

4.
Swigris J, Andrae D, Churney T, Johnson N, Scholand M, White E . Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. Am J Respir Crit Care Med. 2020; 202(12):1689-1697. PMC: 7737580. DOI: 10.1164/rccm.202002-0415OC. View

5.
Swigris J, Esser D, Wilson H, Conoscenti C, Schmidt H, Stansen W . Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017; 49(1). DOI: 10.1183/13993003.01788-2016. View